THE Pharmaceutical Benefits
Advisory Committee has
recommended that the Australian
Government fund Alexion
Pharmaceuticals’ drug Soliris
(eculizumab) for the treatment of
Paroxysmal Nocturnal
Haemoglobinuria (a rare lifethreatening
blood disorder that
causes premature red blood cell
death) through the Life Saving
Drugs Program.
Despite the recommendation, in
order for Soliris to receive the
funding under the scheme, funding
arrangements need to be
negotiated with Alexion
Pharmaceuticals.
In addition, an expert Disease
Advisory Committee is being
established to develop eligibility
and continuation criteria for
patients to receive Soliris
treatment, and treatment
guidelines.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Sep 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Sep 10
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.